| Revision as of 19:28, 19 October 2020 edit128.249.96.13 (talk)No edit summary← Previous edit | Revision as of 21:57, 30 November 2020 edit undo109.255.90.188 (talk) fixNext edit → | ||
| Line 103: | Line 103: | ||
| * 2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (atezolizumab), is approved for the treatment of bladder cancer | * 2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (atezolizumab), is approved for the treatment of bladder cancer | ||
| * 2017 – The first autologous CAR T-cell therapy ] also known as Kymriah is approved for the treatment of pediatric B-ALL. Marketed at a cost of $475,000, the treatment provides an 83% rate of durable remission among poor prognosis patients for whom a bad outcome would otherwise be expected. A second autologous CAR T-cell therapy ] (Yescarta) is approved months later. | * 2017 – The first autologous CAR T-cell therapy ] also known as Kymriah is approved for the treatment of pediatric B-ALL. Marketed at a cost of $475,000, the treatment provides an 83% rate of durable remission among poor prognosis patients for whom a bad outcome would otherwise be expected. A second autologous CAR T-cell therapy ] (Yescarta) is approved months later. | ||
| * 2020 - The first ] is developed for the prevention of ] infection. This |
* 2020 - The first ] is developed for the prevention of ] infection. This new technology allowed design, testing, and potential approval of a prophylactic vaccine in under one year.<ref>Pfizer to seek FDA approval for Covid-19 vaccine in November. https://www.ft.com/content/96614ecd-c854-4582-a1a6-76c050c5c847</ref> | ||
| ==References== | ==References== | ||
| <references /> | <references /> | ||
Revision as of 21:57, 30 November 2020
 |
| Immunology |
|---|
 | This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Timeline of immunology" – news · newspapers · books · scholar · JSTOR (September 2014) (Learn how and when to remove this message) |
Timeline of immunology:
- 1549 – The earliest account of inoculation of smallpox (variolation) occurs in Wan Quan's (1499–1582) Douzhen Xinfa (痘疹心法).
- 1718 – Smallpox inoculation in Ottoman Empire realized by West. Lady Mary Wortley Montagu, the wife of the British ambassador to Constantinople, observed the positive effects of variolation on the native population and had the technique performed on her own children.
- 1796 – First demonstration of smallpox vaccination (Edward Jenner)
- 1808 – 1813 - First experimental demonstration of the germ theory of disease by Agostino Bassi though he does not formally propose the theory until 1844
- 1837 – Description of the role of microbes in putrefaction and fermentation (Theodore Schwann)
- 1838 – Confirmation of the role of yeast in fermentation of sugar to alcohol (Charles Cagniard-Latour)
- 1850 – Demonstration of the contagious nature of puerperal fever (childbed fever) (Ignaz Semmelweis)
- 1857–1870 – Confirmation of the role of microbes in fermentation (Louis Pasteur)
- 1862 – Phagocytosis (Ernst Haeckel)
- 1867 – Aseptic practice in surgery using carbolic acid (Joseph Lister)
- 1876 – Demonstration that microbes can cause disease-anthrax (Robert Koch)
- 1877 – Mast cells (Paul Ehrlich)
- 1878 – Confirmation and popularization of the germ theory of disease (Louis Pasteur)
- 1880 – 1881 -Theory that bacterial virulence could be attenuated by culture in vitro and used as vaccines. Proposed that live attenuated microbes produced immunity by depleting host of vital trace nutrients. Used to make chicken cholera and anthrax "vaccines" (Louis Pasteur)
- 1883 – 1905 – Cellular theory of immunity via phagocytosis by macrophages and microphages (polymorhonuclear leukocytes) (Elie Metchnikoff)
- 1885 – Introduction of concept of a "therapeutic vaccination". Report of a live "attenuated" vaccine for rabies (Louis Pasteur and Pierre Paul Émile Roux).
- 1888 – Identification of bacterial toxins (diphtheria bacillus) (Pierre Roux and Alexandre Yersin)
- 1888 – Bactericidal action of blood (George Nuttall)
- 1890 – Demonstration of antibody activity against diphtheria and tetanus toxins. Beginning of humoral theory of immunity. (Emil von Behring) and (Kitasato Shibasaburō)
- 1891 – Demonstration of cutaneous (delayed type) hypersensitivity (Robert Koch)
- 1893 – Use of live bacteria and bacterial lysates to treat tumors-"Coley's Toxins" (William B. Coley)
- 1894 – Bacteriolysis (Richard Pfeiffer)
- 1896 – An antibacterial, heat-labile serum component (complement) is described (Jules Bordet)
- 1900 – Antibody formation theory (Paul Ehrlich)
- 1901 – Blood groups (Karl Landsteiner)
- 1902 – Immediate hypersensitivity anaphylaxis (Paul Portier) and (Charles Richet)
- 1903 – Intermediate hypersensitivity, the "Arthus reaction" (Maurice Arthus)
- 1903 – Opsonization
- 1905 – "Serum sickness" allergy (Clemens von Pirquet and (Bela Schick)
- 1909 – Paul Ehrlich proposes "immune surveillance" hypothesis of tumor recognition and eradication
- 1911 – 2nd demonstration of filterable agent that caused tumors (Peyton Rous)
- 1917 – Hapten (Karl Landsteiner)
- 1921 – Cutaneous allergic reactions (Otto Prausnitz and Heinz Küstner)
- 1924 – Reticuloendothelial system
- 1938 – Antigen-Antibody binding hypothesis (John Marrack)
- 1940 – Identification of the Rh antigens (Karl Landsteiner and Alexander Weiner)
- 1942 – Anaphylaxis (Karl Landsteiner and Merill Chase)
- 1942 – Adjuvants (Jules Freund and Katherine McDermott)
- 1944 – hypothesis of allograft rejection
- 1945 – Coombs test a.k.a. antiglobulin test (AGT)
- 1946 – Identification of mouse MHC (H2) by George Snell and Peter A. Gorer
- 1948 – Antibody production in plasma B cells
- 1949 – Growth of polio virus in tissue culture, neutralization with immune sera, and demonstration of attenuation of neurovirulence with repetitive passage (John Enders) and (Thomas Weller) and (Frederick Robbins)
- 1951 – vaccine against yellow fever
- 1953 – Graft-versus-host disease
- 1953 – Validation of immunological tolerance hypothesis
- 1957 – Clonal selection theory (Frank Macfarlane Burnet)
- 1957 – Discovery of interferon by Alick Isaacs and Jean Lindenmann
- 1958–1962 – Discovery of human leukocyte antigens (Jean Dausset and others)
- 1959–1962 – Discovery of antibody structure (independently elucidated by Gerald Edelman and Rodney Porter)
- 1959 – Discovery of lymphocyte circulation (James Gowans)
- 1960 – Discovery of lymphocyte "blastogenic transformation" and proliferation in response to mitogenic lectins-phytohemagglutinin (PHA) (Peter Nowell)
- 1961–1962 Discovery of thymus involvement in cellular immunity (Jacques Miller)
- 1960 – Radioimmunoassay – (Rosalyn Sussman Yalow)
- 1961 – Demonstration that glucocorticoids inhibit PHA-induced lymphocyte proliferation (Peter Nowell)
- 1963 – Development of the plaque assay for the enumeration of antibody-forming cells in vitro by Niels Jerne and Albert Nordin
- 1963 – Gell and Coombs classification of hypersensitivity
- 1964–1968 – T and B cell cooperation in immune response
- 1965 – Discovery of lymphocyte mitogenic activity, "blastogenic factor" (Shinpei Kamakura) and (Louis Lowenstein) (J. Gordon) and (L.D. MacLean)
- 1965 – Discovery of "immune interferon" (gamma interferon) (E.F. Wheelock)
- 1965 – Secretory immunoglobulins
- 1967 – Identification of IgE as the reaginic antibody (Kimishige Ishizaka)
- 1968 – Passenger leukocytes identified as significant immunogens in allograft rejection (William L. Elkins and Ronald D. Guttmann)
- 1969 – The lymphocyte cytolysis Cr51 release assay (Theodore Brunner) and (Jean-Charles Cerottini)
- 1971 – Peter Perlmann and Eva Engvall at Stockholm University invented ELISA
- 1972 – Structure of the antibody molecule
- 1973 – Dendritic Cells first described by Ralph M. Steinman
- 1974 – Immune Network Hypothesis (Niels Jerne)
- 1974 – T-cell restriction to MHC (Rolf Zinkernagel and (Peter C. Doherty)
- 1975 – Generation of monoclonal antibodies (Georges Köhler) and (César Milstein)
- 1975 – Discovery of Natural Killer cells (Rolf Kiessling, Eva Klein, Hans Wigzell)
- 1976 – Identification of somatic recombination of immunoglobulin genes (Susumu Tonegawa)
- 1980–1983 – Discovery and characterization of interleukins, 1 and 2 IL-1 IL-2 (Robert Gallo, Kendall A. Smith, Tadatsugu Taniguchi)
- 1983 – Discovery of the T cell antigen receptor TCR (Ellis Reinherz) (Philippa Marrack) and (John Kappler) (James Allison)
- 1983 – Discovery of HIV (Luc Montagnier) (Françoise Barré-Sinoussi) (Robert Gallo)
- 1985–1987 – Identification of genes for the T cell receptor
- 1986 – Hepatitis B vaccine produced by genetic engineering
- 1986 – Th1 vs Th2 model of T helper cell function (Timothy Mosmann)
- 1988 – Discovery of biochemical initiators of T-cell activation: CD4- and CD8-p56lck complexes (Christopher E. Rudd)
- 1990 – Gene therapy for SCID
- 1991 – Role of peptide for MHC Class II structure (Scheherazade Sadegh-Nasseri & Ronald N. Germain)(http://doi.org/10.1038/353167a0)
- 1992 – Discovery of transitional B cells (David Allman & Michael Cancro)
- 1994 – 'Danger' model of immunological tolerance (Polly Matzinger)
- 1995 – James P. Allison describes the function of CTLA-4
- 1995 – Regulatory T cells (Shimon Sakaguchi)
- 1995 – First Dendritic cell vaccine trial reported by Mukherji et al.
- 1996 – 1998 – Identification of Toll-like receptors
- 1997 – Discovery of the autoimmune regulator and the AIRE gene.
- 2000 – Characterization of M1 and M2 macrophage subsets by Charles Mills
- 2001 – Discovery of FOXP3 – the gene directing regulatory T cell development
- 2005 – Development of human papillomavirus vaccine (Ian Frazer)
- 2006 – Antigen-specific NK cell memory first reported by Ulrich von Andrian's group after discovery by Mahmoud Goodarzi
- 2010 – The first autologous cell-based cancer vaccine, PROVENGE, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer. The treatment is marketed at a cost of $93,000 and imparts, on average, only an extra four months of life expectancy. The manufacturer, Dendreon Inc, declares bankruptcy in 2014.
- 2010 – First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA for treatment of stage IV melanoma
- 2011 – Carl H. June reports first successful use of CAR T-cells expressing the 4-1BB costimulatory signaling domain for the treatment of CD19+ malignancies
- 2014 – A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma. Two different drugs, pembrolizumab and nivolumab are approved within months of each other.
- 2016 – Halpert and Konduri first characterize the role of dendritic cell CTLA-4 in Th immune polarization
- 2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (atezolizumab), is approved for the treatment of bladder cancer
- 2017 – The first autologous CAR T-cell therapy tisagenlecleucel also known as Kymriah is approved for the treatment of pediatric B-ALL. Marketed at a cost of $475,000, the treatment provides an 83% rate of durable remission among poor prognosis patients for whom a bad outcome would otherwise be expected. A second autologous CAR T-cell therapy axicabtagene ciloleucel (Yescarta) is approved months later.
- 2020 - The first mRNA vaccine is developed for the prevention of SARS-CoV-2 infection. This new technology allowed design, testing, and potential approval of a prophylactic vaccine in under one year.
References
- Needham, Joseph. (2000). Science and Civilization in China: Volume 6, Biology and Biological Technology, Part 6, Medicine. Cambridge: Cambridge University Press. Page 134.
- Wright, A.E.; Stewart, R.D. (1 September 1903). "An experimental investigation on the role of the blood fluids in connection with phagocytosis". Proceedings of the Royal Society of London. 72 (477–486): 357–370. doi:10.1098/rspl.1903.0062.
- Kolata, Gina (22 January 2015). "Jean Lindenmann, Who Made Interferon His Life's Work, Is Dead at 90". New York Times. Retrieved 12 February 2015.
- Köhler, G; Milstein, C (7 August 1975). "Continuous cultures of fused cells secreting antibody of predefined specificity". Nature. 256 (5517): 495–7. Bibcode:1975Natur.256..495K. doi:10.1038/256495a0. PMID 1172191.
- Haskins, K; Kubo, R; White, J; Pigeon, M; Kappler, J; Marrack, P (1 April 1983). "The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody". The Journal of Experimental Medicine. 157 (4): 1149–69. doi:10.1084/jem.157.4.1149. PMC 2186983. PMID 6601175.
- Allman, DM; Ferguson, SE; Cancro, MP (15 October 1992). "Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics". Journal of Immunology. 149 (8): 2533–40. PMID 1383316.
- Allman, DM; Ferguson, SE; Lentz, VM; Cancro, MP (1 November 1993). "Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells". Journal of Immunology. 151 (9): 4431–44. PMID 8409411.
- Mills CD; et al. (2000). "M-1/M-2 Macrophages and the Th1/Th2 Paradigm". J Immunol. 164 (12): 6166–6173. doi:10.4049/jimmunol.164.12.6166. PMID 10843666.
- Pfizer to seek FDA approval for Covid-19 vaccine in November. https://www.ft.com/content/96614ecd-c854-4582-a1a6-76c050c5c847
| History of biology (timeline) | |
|---|---|
| Fields, disciplines | |
| Theories, concepts | |
| Related | |
| History of medicine | ||
|---|---|---|
| Timeline of medicine and medical technology | ||
| Histories of basic sciences |  | |
| Histories of medical specialties | ||
| Medicine in ancient societies | ||
| History of methods in medicine | ||
| Disasters and plagues | ||